Lagatar24 Desk
Seoul: Chronic kidney disease (CKD) poses a serious global health challenge, marked by the gradual decline of kidney function. Early detection and intervention are crucial for maintaining kidney health and preventing severe complications. In a breakthrough development, a team of researchers from Chung-Ang University in the Republic of Korea has introduced a new, non-invasive testing method to detect early signs of kidney disease by measuring SDMA (symmetric dimethylarginine) levels in urine.
SDMA is a byproduct of protein metabolism and serves as a reliable indicator of kidney function. Unlike traditional methods that measure creatinine levels, which may only show abnormalities after more than 75% of kidney function is lost and can be influenced by muscle mass, SDMA levels rise even with a 25–40% loss of kidney function. This makes it a more sensitive and accurate marker for early-stage kidney issues.
How the Biosensor Works
Professor Jong Pil Park, the lead author of the study, highlighted the critical need for early diagnostic tools. “Kidney disease is often detected at a late stage, limiting treatment options. We aimed to develop a tool that can be easily used by patients and clinicians to monitor kidney health and enable timely intervention for better outcomes,” said Prof. Park.
The newly developed biosensor provides several advantages over traditional testing. It offers higher sensitivity and requires no advanced laboratory equipment, making it accessible in a variety of settings, including smaller clinics and areas with limited resources. “The simple design and rapid results make this biosensor an excellent option for regular health check-ups and continuous monitoring,” the research team noted.
Impact on Global Healthcare
The researchers emphasized that this innovation could be a game-changer for patient care worldwide. “Our biosensor could enable earlier diagnosis and improved treatment outcomes for millions of people,” Prof. Park stated. He also pointed out the versatility of the platform, noting its potential to be adapted for detecting other biomarkers and extending its application across different areas of healthcare.
